List of Antara (micronized) drug patents
Antara (Micronized) is owned by Lupin.
Antara (Micronized) contains Fenofibrate.
Antara (Micronized) has a total of 2 drug patents out of which 0 drug patents have expired.
Antara (Micronized) was authorised for market use on 30 November, 2004.
Antara (Micronized) is available in capsule;oral dosage forms.
Antara (Micronized) can be used as treating severe hypertriglyceridemia; treating primary hypercholesterolemia and mixed dyslipidemia, treating primary hypercholesterolemia and mixed dyslipidemia; treating severe hypertriglyceridemia.
The generics of Antara (Micronized) are possible to be released after 31 May, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8026281 | LUPIN | Treating metabolic syndrome with fenofibrate |
Apr, 2025
(2 years from now) | |
| US9314447 | LUPIN | Reduced dose pharmaceutical compositions of fenofibrate |
May, 2033
(10 years from now) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 30 November, 2004
Treatment: Treating severe hypertriglyceridemia; Treating primary hypercholesterolemia and mixed dyslipidemia
Dosage: CAPSULE;ORAL
ANTARA (MICRONIZED) family patents
3
United States
1
Switzerland
1
IB
1
India
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic